2,3-dinor-thromboxane b2 and Innate Inflammatory Response

2,3-dinor-thromboxane b2 has been researched along with Innate Inflammatory Response in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cheng, Y; Cyrus, T; Ding, T; Falotico, R; Ma, M; Praticò, D; Tian, H; Zhao, L	1

Other Studies

1 other study(ies) available for 2,3-dinor-thromboxane b2 and Innate Inflammatory Response

Article	Year
Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. British journal of pharmacology, 2009, Volume: 156, Issue:5 Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Atherosclerosis; Cholesterol; Collagen; Creatinine; Cytokines; Diet, Atherogenic; Dose-Response Relationship, Drug; Inflammation; Isoprostanes; Male; Mice; Mice, Knockout; Random Allocation; Receptors, LDL; Sirolimus; Thromboxane B2; Time Factors; Triglycerides	2009

Article

Year

Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor.

British journal of pharmacology, 2009, Volume: 156, Issue:5

Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Atherosclerosis; Cholesterol; Collagen; Creatinine; Cytokines; Diet, Atherogenic; Dose-Response Relationship, Drug; Inflammation; Isoprostanes; Male; Mice; Mice, Knockout; Random Allocation; Receptors, LDL; Sirolimus; Thromboxane B2; Time Factors; Triglycerides

2009